MedTrace Logo

African Glaucoma Laser Trial

NCT03648229 · Status: WITHDRAWN · Phase: PHASE4 · Type: INTERVENTIONAL

Last updated 2021-06-21

No results posted yet for this study

Summary

The AGLT is a prospective, multicenter, randomized study in which adult black Africans with treatment-naive open-angle glaucoma are assigned to therapy with selective laser trabeculoplasty (SLT), medications provided at no cost (MED), or medications provided by prescription for subjects to obtain at their own expense as per usual care (RX). The overall goal of the AGLT is to determine the best treatment strategy for newly-diagnosed open-angle glaucoma in Africa.

Conditions

  • Open-angle Glaucoma

Interventions

PROCEDURE

Selective laser trabeculoplasty (SLT)

Delivery of laser energy to the trabecular meshwork of the eye with the goal of reducing intraocular pressure

DRUG

Latanoprost ophthalmic solution

Prostaglandin analogue topical ophthalmic medication for reduction of intraocular pressure

DRUG

Timolol ophthalmic solution

Timolol ophthalmic solution 0.5% for reduction of intraocular pressure

Sponsors & Collaborators

  • University of Pittsburgh

    collaborator OTHER

  • University of Michigan

    collaborator OTHER

  • West Virginia University

    lead OTHER

Principal Investigators

  • Anthony D Realini, MD · West Virginia University Eye Institute

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-09-01
Primary Completion
2022-06-30
Completion
2024-06-30
FDA Drug
Yes

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03648229 on ClinicalTrials.gov